Meg Ives Quoted in Life Sciences IP Review

Life Sciences IP Review recently quoted Meg Ives in its article "LSPN 19: Humira litigation may prompt more antitrust scrutiny". The article, which was written in coverage of Meg's presentation at last week's Life Sciences Patent Network event, discusses six antitrust class-action lawsuits that have been brought against AbbVie over its arthritis treatment, Humira. The article focuses on how these suits could result in more scrutiny of settlement agreements between innovators and manufacturers, with potential antitrust complications.

From the article:

There's a real question whether this will delay the potential settlement of these cases,” added Ives. “But given the likelihood of additional scrutiny and potential lawsuits from third parties, it’s definitely going to upset some of the timelines on when these cases might get solved.

To read the full version of the article, click here.